☆ 4.7 Article

Antibody cocktail effective against variants of SARS-CoV-2

JOURNAL OF BIOMEDICAL SCIENCE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Erik Volz et al.

Summary: The study suggests a positive selection for the SARS-CoV-2 spike protein variant D614G in the UK, but no evidence of differences in COVID-19 mortality or clinical severity in patients infected with this variant. 614G is associated with higher viral load and younger age of patients compared to 614D.

CELL (2021)

添加到收藏夹

Article Microbiology

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Zhuoming Liu et al.

Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.

CELL HOST & MICROBE (2021)

添加到收藏夹

Review Microbiology

The variant gambit: COVID-19's next move

Jessica A. Plante et al.

Summary: Despite the development of vaccines, COVID-19 caused by SARS-CoV-2 continues to be a global concern due to the emergence of new variants, raising worries about increased spread and potential impacts on immunity.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike D614G change enhances replication and transmission

Bin Zhou et al.

Summary: Research has shown that the D614G substitution in the spike protein of SARS-CoV-2 leads to increased binding and replication potential in humans, as well as significantly higher replication and transmissibility in different animal models, providing an explanation for the global prevalence of this variant in the COVID-19 pandemic.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Robert Challen et al.

Summary: The study found that the mortality hazard ratio associated with infection with VOC-202012/1 compared with previously circulating variants was 1.64, indicating an increase in deaths from 2.5 to 4.1 per 1000 detected cases in comparatively low risk group of covid-19 patients in the community. This suggests that infection with VOC-202012/1 may lead to substantial additional mortality compared with previously circulating variants, impacting healthcare capacity planning and control policies.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Microbiology

Structure-guided antibody cocktail for prevention and treatment of COVID-19

Shih-Chieh Su et al.

Summary: The study developed a series of chimeric antibodies targeting the RBD of the SARS-CoV-2 spike protein, with some exhibiting exceptionally potent neutralizing activities. Cryo-electron microscopy analyses of two highly potent antibodies complexed with the SARS-CoV-2 spike protein suggested they may be particularly useful when combined in a cocktail therapy.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Microbiology

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Pengfei Wang et al.

Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Nicholas G. Davies et al.

Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Erik Volz et al.

Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.

NATURE (2021)

添加到收藏夹

Letter Medicine, General & Internal

New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications

Salim S. Abdool Karim et al.

Summary: The emergence of SARS-CoV-2 variants, including B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1), has raised concerns about worsening Covid-19 and potential escape from vaccine-induced immunity.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cell Biology

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Bryan E. Jones et al.

Summary: LY-CoV555 is a novel neutralizing antibody derived from a convalescent patient with COVID-19, showing high affinity binding, potent inhibition of ACE2 binding, and strong neutralizing activity. This antibody has entered clinical trials and is being evaluated for various COVID-19 prevention and treatment indications.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Chihiro Motozono et al.

Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

DELTA CORONAVIRUS VARIANT: SCIENTISTS BRACE FOR IMPACT

Ewen Callaway

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Emergence and expansion ofSARS-CoV-2 B.1.526 after identification in New York

Medini K. Annavajhala et al.

Summary: The emergence of the B.1.526 lineage of SARS-CoV-2, with mutations such as E484K, has led to its rapid dominance in New York City. This variant is resistant to therapeutic monoclonal antibodies and less susceptible to neutralization by antibodies from recovered or vaccinated individuals, contributing to its fast spread.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function

Tzu-Jing Yang et al.

Summary: The spike protein of the SARS-CoV-2 B.1.1.7 variant exhibits mutations that affect virus binding to the host ACE2 receptor and immune evasion. The A570D and N501Y mutations have been shown to impact the stability of the spike protein structure, and an introduced neutralizing antibody can effectively neutralize different strains of the virus.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Meng Yuan et al.

Summary: Mutations in the RBS residues of new variant strains of the coronavirus can affect the binding and neutralizing effects of antibodies, but have little impact on antibodies targeting more conserved neutralizing sites.

SCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Gabriele Cerutti et al.

Summary: Emerging SARS-CoV-2 variants pose clinical concerns due to reduced neutralization by certain antibodies, but antibodies targeting specific regions may still be effective in bypassing mutations and providing potential therapeutic benefits.

STRUCTURE (2021)

添加到收藏夹

Article Microbiology

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

Hao Zhou et al.

Summary: A new SARS-CoV-2 variant B.1.526 has been identified in New York City and is spreading rapidly, but current evidence suggests that vaccine-elicited antibodies and Regeneron therapeutic monoclonal antibodies remain effective in combating the B.1.526 variant.

MBIO (2021)

添加到收藏夹

Article Cell Biology

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Markus Hoffmann et al.

Summary: The emergence of the B.1.617 variant in India may be responsible for the sharp increase in COVID-19 cases and deaths. B.1.617 shows increased efficiency in entering cells and evades antibody responses, contributing to its rapid spread.

CELL REPORTS (2021)

添加到收藏夹

Article Microbiology

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Jinhui Dong et al.

Summary: Structural analysis of two human monoclonal antibodies forming the antibody cocktail AZD7442, when bound to the RBD of SARS-CoV-2, demonstrates strong neutralization of variants of concern. Genetic and structural basis of neutralization has been defined, revealing crucial binding residues and positions of concern for virus escape. These germ line-encoded antibody features enable recognition of SARS-CoV-2 spike RBD and showcase the utility of cocktail AZD7442 in neutralizing emerging variant viruses.

NATURE MICROBIOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Victor M. Corman et al.

EUROSURVEILLANCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sin Fun Sia et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Tyler N. Starr et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

Leonid Yurkovetskiy et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Hongjing Gu et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Zhe Lv et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Tal Noy-Porat et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Cell Biology

Development of therapeutic antibodies for the treatment of diseases

Ruei-Min Lu et al.

JOURNAL OF BIOMEDICAL SCIENCE (2020)

添加到收藏夹

Review Medicine, Research & Experimental

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori et al.

MABS (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.